Figure 3

Efficacy measures. A. LS mean change from baseline to endpoint in PANSS total score in the LY2140023 and SOC treatment groups estimated from the MMRM model; error bars indicate standard error. Mean PANSS total score at baseline (SD): LY2140023: 85.6 (14.8); SOC: 85.1 (15.8). For the PANSS Total Score, there was a significant effect of baseline (Overall MMRM, F [1,277] = 55.10, P < .001), and a significant effect of treatment (Overall MMRM, F [1,173] = 4.20, P = .042). B. LS mean change from baseline to endpoint in NSA-16 total score in the LY2140023 and SOC treatment groups estimated from the MMRM model; error bars indicate standard error. Mean NSA-16 total score at baseline (SD): LY2140023: 58.7(11.0); SOC: 57.3 (11.3). For the NSA-16 Total Score, there was a significant effect of baseline (Overall MMRM, F [1,207] = 36.55, P < .001), but not a significant effect of treatment (Overall MMRM, F [1,180] = 0.39, P = .532). Abbreviations: LS = least squares; MMRM = mixed-model repeated measures; NSA-16 = 16-item Negative Symptoms Assessment scale; PANSS = Positive and Negative Syndrome Scale; vs. = versus. Groups: LY2140023 = LY2140023 monohydrate, SOC = standard-of-care. *P < .05, LY2140023 versus SOC.